Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New directions in anticoagulant and antiplatelet treatment.

× No keyword cloud information.

20 in total

Review 1. Heparin.

Authors: J Hirsh
Journal: N Engl J Med Date: 1991-05-30 Impact factor: 91.245

2. Selective thrombin inhibitors: the next generation of anticoagulants.

Authors: E Deutsch; A K Rao; R W Colman
Journal: J Am Coll Cardiol Date: 1993-10 Impact factor: 24.094

3. NHLBI funding policies. Enhancing stability, predictability, and cost control.

Authors: C Lenfant
Journal: Circulation Date: 1994-07 Impact factor: 29.690

4. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.

Authors: M Verstraete; M Nurmohamed; J Kienast; M Siebeck; G Silling-Engelhardt; H Büller; B Hoet; J Bichler; P Close
Journal: J Am Coll Cardiol Date: 1993-10 Impact factor: 24.094

5. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.

Authors: P Zoldhelyi; M W Webster; V Fuster; D E Grill; D Gaspar; S J Edwards; C F Cabot; J H Chesebro
Journal: Circulation Date: 1993-11 Impact factor: 29.690

6. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.

Authors: A A van den Bos; J W Deckers; G R Heyndrickx; G J Laarman; H Suryapranata; F Zijlstra; P Close; J J Rijnierse; H R Buller; P W Serruys
Journal: Circulation Date: 1993-11 Impact factor: 29.690

7. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.

Authors: M L Simoons; M J de Boer; M J van den Brand; A J van Miltenburg; J C Hoorntje; G R Heyndrickx; L R van der Wieken; D de Bono; W Rutsch; T F Schaible
Journal: Circulation Date: 1994-02 Impact factor: 29.690

8. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.

Authors: C P Cannon; J M Maraganore; J Loscalzo; A McAllister; K Eddings; D George; A P Selwyn; B Adelman; I Fox; E Braunwald
Journal: Am J Cardiol Date: 1993-04-01 Impact factor: 2.778

9. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.

Authors: C P Cannon; C H McCabe; T D Henry; M J Schweiger; R S Gibson; H S Mueller; R C Becker; N S Kleiman; J M Haugland; J L Anderson
Journal: J Am Coll Cardiol Date: 1994-04 Impact factor: 24.094

10. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.

Authors: E J Topol; R M Califf; H F Weisman; S G Ellis; J E Tcheng; S Worley; R Ivanhoe; B S George; D Fintel; M Weston
Journal: Lancet Date: 1994-04-09 Impact factor: 79.321